Clinical trials: sponsored by University of Oxford
Tuberculosis
ID93/GLA-SE Vaccination + BCG Challenge
The purpose of this study is to: 1. Demonstrate the safety of a novel TB vaccine (ID93/GLA-SE) when given to both BCG-vaccinated and BCG-naïve volunteers. 2.
- Trial name
- NCT06670755
- Testing
- ID93/GLA-SE, BCG Danish
- Where
- United Kingdom
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Pre-eclampsia
Oxford Luteal Dysfunction and Placental Insufficiency Study
High blood pressure (BP) affects approximately 1 in 10 pregnancies. About half of women with high blood pressure in pregnancy develop a serious complication called preeclampsia, which kills over 70,000 women and 500,000 babies…
- Trial name
- OxLuPIn (NCT07072052)
- Testing
- No intervention planned
- Where
- United Kingdom
- Volunteers
- 360 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Spinal Muscular Atrophy (SMA)
Service Evaluation for Newborn Screening for Spinal Muscular Atrophy
Spinal Muscular Atrophy (SMA) is a disease that causes progressive muscle weakness. There are many types- the most severe and most common, type 1, affects very young babies, and is life-threatening if untreated.
- Trial name
- SENS (NCT07888868)
- Where
- 3 sites in United Kingdom
- Volunteers
- 750,000 people
- Sponsor
- University of Oxford
Malaria,Falciparum
A Study to Test Experimental Blood Stage Malaria Vaccine in Burkina Faso.
This is a Phase IIb randomised controlled trial of the safety, immunogenicity and efficacy of the blood-stage malaria vaccine candidates RH5.1 in Matrix-MTM and RH5.2-VLP in Matrix-MTM in infants aged 5-17 months in Burkina Faso
- Trial name
- NCT05790889
- Testing
- Rabies vaccine, RH5.1 10μg adjuvated with 50μg Matrix-M, RH5.2 5μg adjuvated with 50μg Matrix-M
- Where
- Burkina Faso
- Volunteers
- 390 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Malaria,Falciparum
A Phase 1 Study to Assess an Escalating Dose, Multi-prime Vaccination Schedule of R21/Matrix-M™
This is a phase I clinical study that aims to assess the safety and immunogenicity of a novel, escalating dose regimen of R21/Matrix-M™ in healthy, malaria-naïve adults.
- Trial name
- NCT06320535
- Testing
- R21/Matrix M™ (Group 1), R21/Matrix M™ (Group 2), R21/Matrix M™ (Group 3)
- Where
- 2 sites in United Kingdom
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Malaria,Falciparum
A Study to Assess the Experimental Malaria Vaccines R78C and RH5.1 Combined With R21/Matrix-M (a "Multi-stage" Malaria Vaccine)
This is a Phase Ib age de-escalation, dose escalation, open-label study to assess the safety and immunogenicity of the multi-stage malaria vaccine candidate R21 plus RH5.1 and/or R78C in Matrix-M in adults aged 18-35 years and…
- Trial name
- VAC093 (NCT06958198)
- Testing
- R21, RH5.1, R78C
- Where
- Burkina Faso
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Malaria,Falciparum
A Study to Assess the Experimental Malaria Vaccines R78C and RH5.1 With Matrix-M in Combination With R21/Matrix-M
This is a Phase IIb randomised controlled trial of the safety, immunogenicity and efficacy of the malaria vaccine candidates R78C with Matrix-M™, and the combination of RH5.1 and R21 with Matrix-M™, in children aged 5-36 months…
- Trial name
- VAC087 (NCT07183371)
- Testing
- R21, RH5.1, R78C
- Where
- Burkina Faso
- Volunteers
- 360 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Retinal Vein Occlusion (RVO)
Robotic RVO Trial: Robot-assisted Retinal Vein Cannulation in Patients With Retinal Vein Occlusions
Retinal vein occlusions (RVOs) are the second leading cause of permanent vision loss in the UK. Current treatments, like anti-VEGF injections or steroids, address complications such as macular fluid but do not target the…
- Trial name
- RVO (NCT07820761)
- Testing
- Surgery with Preceyes Robot plus NHS standard of care
- Where
- United Kingdom
- Volunteers
- 40 people
- Sponsor
- University of Oxford
Artificial Intelligence Perception and Attitude
What Should we Measure? A Qualitative Interview Study on Outcomes for Evaluating AI-assisted Medical Image Interpretation.
Background: AI (artificial intelligence) tools are increasingly used to help clinicians interpret medical images such as X-rays, scans, skin photographs and eye images.
- Trial name
- NCT07885150
- Where
- United Kingdom
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Plasmodium Vivax Malaria
Southeast Asia Dose Optimization of Tafenoquine
Tafenoquine was recently approved by regulatory authorities in the USA and Australia. Tafenoquine is an alternative radical curative treatment to primaquine acting against the dormant liver stage of Plasmodium vivax (the…
- Trial name
- SEADOT (NCT04704999)
- Testing
- Tafenoquine, Chloroquine, Artemether 20 mg-Lumefantrine 120 mg
- Where
- 6 sites in Cambodia, Indonesia and 3 more
- Volunteers
- 820 people
- Sponsor
- University of Oxford
Major Depressive Disorder (MDD)
Prescribing the Right Agent for Depression in Adults
Depression is a common mental health problem affecting almost 300 million people worldwide. Antidepressants are recommended as one of the first line treatments for people with moderate-to-severe symptoms of depression.
- Trial name
- PRADA (NCT07796295)
- Testing
- PRADA Tool, PETRUSHKA Tool
- Where
- 3 sites in Ethiopia, Pakistan and 1 more
- Volunteers
- 2,142 people
- Sponsor
- University of Oxford
Psychosis, First Episode Psychosis
Stratification and Treatment in Early Psychosis Study - ENHANCE
The purpose of this study is: To investigate whether the response to antipsychotic treatment can be enhanced by adding cannabidiol (CBD) to the existing treatment, compared to placebo, in participants with a first episode of…
- Conditions
- Psychosis, First Episode Psychosis, Psychotic Disorders, Psychotic Episode
- Trial name
- STEP-ENHANCE (NCT06778564)
- Testing
- CBD 100 mg/mL Oral Solution
- Where
- 17 sites in Austria, Germany and 7 more
- Volunteers
- 250 people
- Sponsor
- University of Oxford
Treatment Resistant Psychosis, Psychosis
Stratification and Treatment in Early Psychosis Study -ASSIST
The purpose of this trial is: To investigate whether the response to clozapine treatment can be enhanced by adding cannabidiol (CBD), compared to placebo, in treatment resistant psychosis patients.
- Trial name
- STEP-ASSIST (NCT07326124)
- Testing
- CBD 100 mg/mL Oral Solution, Placeb
- Where
- 15 sites in Germany, Greece and 6 more
- Volunteers
- 250 people
- Sponsor
- University of Oxford
Clinical High Risk for Psychosis (CHR), Clinical High Risk for Psychosis
Stratification and Treatment in Early Psychosis Study - PROMOTE
The purpose of this trial is: To investigate whether cannabidiol (CBD), compared to placebo, can reduce the severity of attenuated psychotic symptoms in individuals at clinical high risk for psychosis.
- Conditions
- Clinical High Risk for Psychosis (CHR), Clinical High Risk for Psychosis, Clinical High Risk for Developing Psychosis
- Trial name
- STEP-PROMOTE (NCT07434973)
- Testing
- Cannabidiol (CBD)
- Where
- 19 sites in Austria, Canada and 8 more
- Volunteers
- 586 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Antimicrobial Stewardship
Evidence Based QUality Improvement for Prescribing Stewardship in ICU (EQUIPS-ICU)
The goal of this observational study is to learn about the implementation of a process to review antimicrobial prescriptions for adult patients in Intensive Care Unit (ICU).
- Trial name
- EQUIPS-ICU (NCT06666738)
- Testing
- Structured antimicrobial review
- Where
- Vietnam
- Volunteers
- 6,300 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Low Mood, Depression - Major Depressive Disorder
PROMOTE: Effects of 5-HT4 Agonism on Cognition and Sleep in Peopl With Low Mood
Serotonin is a chemical in the brain that plays an important role in mood, sleep, and other functions. It works by attaching to different types of serotonin receptors on brain cells.
- Trial name
- PROMOTE (NCT07848477)
- Testing
- Prucalopride
- Where
- United Kingdom
- Volunteers
- 60 people
- Sponsor
- University of Oxford
Emotional Processing, Cognition
7T Amygdala and Citalopram Study
The goal of this study is to investigate how a common antidepressant citalopram (which increases the levels of the chemical messenger serotonin), affects how a key area of the brain involved in depression (the amygdala) responds…
- Conditions
- Emotional Processing, Cognition, Mood Disorders, Depressive Disorder
- Trial name
- 7T FACES (NCT06412315)
- Testing
- Citalopram
- Where
- United Kingdom
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Febrile Illness
Incidences, Causes, and Outcomes of Febrile Illness in Rural South and Southeast Asia
The study will collect information to understand the causes and outcomes of febrile illness in rural areas in countries across South and Southeast Asia (including Cambodia, Laos, Myanmar and Bangladesh).
- Trial name
- SEACTN-WP-A (NCT04478578)
- Where
- 7 sites in Bangladesh, Burma and 3 more
- Volunteers
- 82,760 people
- Sponsor
- University of Oxford
Social Cognition
Losartan and Social Processing
This study explores the effects of single-dose losartan (50mg) versus placebo on social processing in healthy volunteers.
- Trial name
- NCT06624904
- Testing
- Losartan potassium 50mg
- Where
- United Kingdom
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Sepsis
Use of Procalcitonin, a Blood Test to Guide Antibiotic Therapy for Sepsis in Adults
Trial design: Randomised controlled, two-arm, parallel, clinical trial to assess the efficacy and safety of sequential daily procalcitonin assessments to guide de-escalation of empirical antibiotic therapy in adult patients with…
- Trial name
- PROCALBAN (NCT05955612)
- Testing
- Procalcitonin measurement
- Where
- Bangladesh
- Volunteers
- 532 people
- Sponsor
- University of Oxford